Clinicians Laura Huppert, Kelsey Natsuhara, and Magdelena Ford discuss the evidence, challenges, and real-world ...
TipRanks on MSN
Wellgistics Health launches diabetes drug Brenzavvy
Wellgistics Health Inc ( ($WGRX) ) has issued an update. On December 8, 2025, Wellgistics Health, Inc. announced the commercial launch of its ...
An international research team has uncovered a surprising ally in the fight against insulin resistance and type 2 diabetes: a ...
A review article discussed the expanding role of biologics in treating components of metabolic syndrome, including glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes and obesity and ...
The FDA has granted accelerated approval to Otsuka’s Voyxact for adults with primary IgAN at risk of disease progression, ...
Type 2 Diabetes (T2D) is a major public health challenge, with India ranking second globally in prevalence. [1] The ...
(Reuters) -Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight ...
Background: The impact of sodium–glucose cotransporter-2 inhibitors (SGLT2i) on post-ablation atrial fibrillation (AF) recurrence is still unclear. Accordingly, we investigated whether exposure to ...
HOUSTON — The benefits of SGLT2 inhibitors in slowing kidney disease progression are similar regardless of patients’ type 2 diabetes (T2D) or albuminuria status, the results of a recent meta-analysis ...
Why is this study important? People with type 2 diabetes have 2-4 times the risk of heart attack, stroke, and other cardiovascular events compared to those without diabetes. The diabetes drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results